Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Liothyronine injection | ||
|
Liraglutide (Saxenda®) (GLP1s should all be prescribed by brand name) | The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Saxenda®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. |
|
|
Lisdexamfetamine | ESCAs and additional advice in relation to age of patient and CCG |
|
|
Lofexidine | Hospital only |
|
|
Lomitapide | Homozygous familial hypercholesterolaemia - hospital only |
|
|
Lomustine capsules | ||
|
Loprazolam injection | ||
|
Lorazepam | ||
|
Lorazepam injection | ||
|
Lorlatinib (Lorviqua®) |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
